Thermo Fisher Scientific Inc. (NYSE:TMO) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seventeen brokerages that are covering the company, MarketBeat reports. Five analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $607.35.

A number of analysts have issued reports on the company. Royal Bank of Canada lifted their price objective on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an "outperform" rating in a research note on Thursday, February 1st. Evercore ISI upped their price objective on Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an "outperform" rating in a research report on Thursday, April 4th. Barclays upped their price objective on Thermo Fisher Scientific from $590.00 to $615.00 and gave the company an "equal weight" rating in a research report on Thursday, April 25th. Robert W. Baird lowered their target price on Thermo Fisher Scientific from $621.00 to $620.00 and set an "outperform" rating for the company in a report on Thursday, April 25th. Finally, JPMorgan Chase & Co. upped their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an "overweight" rating in a report on Thursday, April 25th.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock traded up $0.68 on Wednesday, reaching $590.80. The stock had a trading volume of 871,441 shares, compared to its average volume of 1,510,454. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68. The business's 50 day moving average is $576.49 and its two-hundred day moving average is $545.39. The company has a market cap of $225.52 billion, a P/E ratio of 37.85, a price-to-earnings-growth ratio of 2.46 and a beta of 0.80. Thermo Fisher Scientific has a 1 year low of $415.60 and a 1 year high of $603.82.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating analysts' consensus estimates of $4.70 by $0.41. The firm had revenue of $10.35 billion during the quarter, compared to analyst estimates of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. As a group, research analysts anticipate that Thermo Fisher Scientific will post 21.65 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Friday, June 14th will be paid a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.26%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.01%.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total value of $5,724,100.00. Following the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $70,873,516.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the business's stock in a transaction on Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the sale, the senior vice president now directly owns 13,083 shares of the company's stock, valued at approximately $7,430,359.02. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $70,873,516.56. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,000 shares of company stock valued at $18,486,980. Corporate insiders own 0.34% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. WealthPlan Investment Management LLC increased its stake in shares of Thermo Fisher Scientific by 239.4% during the 3rd quarter. WealthPlan Investment Management LLC now owns 3,394 shares of the medical research company's stock worth $1,718,000 after purchasing an additional 2,394 shares during the last quarter. Bahl & Gaynor Inc. grew its holdings in Thermo Fisher Scientific by 4.9% in the third quarter. Bahl & Gaynor Inc. now owns 3,366 shares of the medical research company's stock worth $1,704,000 after purchasing an additional 156 shares during the period. Certuity LLC lifted its position in shares of Thermo Fisher Scientific by 30.4% during the third quarter. Certuity LLC now owns 690 shares of the medical research company's stock valued at $349,000 after purchasing an additional 161 shares in the last quarter. ORG Partners LLC increased its stake in shares of Thermo Fisher Scientific by 18.5% in the third quarter. ORG Partners LLC now owns 982 shares of the medical research company's stock worth $497,000 after purchasing an additional 153 shares in the last quarter. Finally, Fiducient Advisors LLC purchased a new position in Thermo Fisher Scientific during the third quarter valued at approximately $1,060,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.